Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria
- 1 February 1993
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 37 (2) , 354-356
- https://doi.org/10.1128/aac.37.2.354
Abstract
Mutations which severely affect the function of the outer membrane of Escherichia coli and Salmonella typhimurium (lpxA and firA mutations of lipid A synthesis and rfaE mutation of the lipopolysaccharide inner-core synthesis) were found to decrease the MICs of erythromycin, roxithromycin, clarithromycin, and azithromycin by factors of 32 to 512, 32 to 1,024, 64 to 512, and 16 to 64, respectively. The sensitization factors for three other hydrophobic antibiotics (rifampin, fusidic acid, and mupirocin) ranged from 16 to 300. The outer membrane permeability-increasing agents polymyxin B nonapeptide (3 micrograms/ml) and deacylpolymyxin B (1 microgram/ml) sensitized wild-type E. coli to azithromycin by factors of 10 and 30, respectively. Quantitatively very similar sensitization to the other macrolides took place. Polymyxin-resistant pmrA mutants of S. typhimurium displayed no cross-resistance to azithromycin. Proteus mirabilis mutants which were sensitized to polymyxin by a factor of > or = 300 to > or = 1,000 had a maximal two- to fourfold increase in sensitivity to azithromycin. These results indicate that azithromycin and the other new macrolides use the hydrophobic pathway across the outer membrane and that the intact outer membrane is an effective barrier against them. Furthermore, the results indicate that azithromycin, in contrast to polymyxin, does not effectively diffuse through the outer membrane by interacting electrostatically with the lipopolysaccharide.Keywords
This publication has 13 references indexed in Scilit:
- The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibilityAntimicrobial Agents and Chemotherapy, 1992
- Influence of outer membrane mutations on susceptibility of Escherichia coli to the dibasic macrolide azithromycinJournal of Antimicrobial Chemotherapy, 1992
- The outer membrane permeability-increasing action of deacylpolymyxins.The Journal of Antibiotics, 1991
- New directions for macrolide antibiotics: structural modifications and in vitro activityAntimicrobial Agents and Chemotherapy, 1989
- Comparative in vitro activity of the new oral macrolide azithromycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1988
- Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organismsAntimicrobial Agents and Chemotherapy, 1987
- Proteus mirabilis: Taxonomic Position, Peculiarities of Growth, Components of the Cell EnvelopePublished by Springer Nature ,1986
- Molecular basis of bacterial outer membrane permeability.1985
- EM49: A NEW POLYPEPTIDE ANTIBIOTIC ACTIVE AGAINST CELL MEMBRANESAnnals of the New York Academy of Sciences, 1974
- Non-smooth Mutants of Salmonella typhimurium: Differentiation by Phage Sensitivity and Genetic MappingJournal of General Microbiology, 1972